Adenomatous Polyposis Coli
12
1
1
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.7%
2 terminated out of 12 trials
75.0%
-11.5% vs benchmark
17%
2 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Sirolimus and Familial Adenomatous Polyposis (FAP)
Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis
Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis